LncRNA MT1JP Suppresses Biological Activities of Breast Cancer Cells in Vitro and in Vivo by Regulating the MiRNA-214/RUNX3 Axis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Jun 26

PMID 32581560

Citations 9

Authors

Qianwen Ouyang

Yanru Cui

Shixin Yang

Wensong Wei

Mingyue Zhang

Jie Zeng

Fei Qu

Affiliations

Soon will be listed here.

Abstract

Introduction: The purpose of our research was to evaluate MT1JP in breast cancer.

Material And Methods: For clinical purpose, tissues were collected, and a correlation analysis ofMT1JP and miRNA-214 gene expressions was conducted. Using an in vitro study, MDA-MB-231 and MCF-7 cell lines were used as research objects in our research. Colony, flow cytometry, TUNEL, transwell, adhesion and wound healing assay were used to discuss the biological activities of the cells. In an in vivo study, tumor weight and volume were measured, and cell apoptosis was measured by TUNEL assay. The relative mechanism's proteins were evaluated by Western blotting or immunohistochemistry assay.

Results: Compared with adjacent tissues, MT1JP and miRNA-214 gene expressions were significantly different (P<0.001, respectively). By in vitro and in vivo studies, the biological activities of the cells were significantly decreased in MDA-MB-231 and MCF-7 cell lines with MT1JP overexpression. The relative mechanism was correlated with miRNA-214/RUNX3 axis.

Conclusion: The overexpression of MT1JP suppresses the biological activities of breast cancer cells by regulation miRNA-214/RUNX3 axis in vitro and vivo study.

Citing Articles

The impact of ferroptosis and ferroptosis-related non-coding RNAs on breast cancer progression.

Liu W, Jiang C, Ma Y, Wang W, Peng J, Ma W Front Cell Dev Biol. 2025; 12:1506492.

PMID: 39763590 PMC: 11701165. DOI: 10.3389/fcell.2024.1506492.

Exploring the clinical potential of circulating LncRNAs in breast cancer: insights into primary signaling pathways and therapeutic interventions.

Al-Noshokaty T, Abdelhamid R, Reda T, Alaaeldien A, Abdellatif N, Mansour A Funct Integr Genomics. 2024; 24(6):209.

PMID: 39508907 DOI: 10.1007/s10142-024-01476-y.

Anti-cancer effect and potential microRNAs targets of ginsenosides against breast cancer.

Fan M, Shan M, Lan X, Fang X, Song D, Luo H Front Pharmacol. 2022; 13:1033017.

PMID: 36278171 PMC: 9581320. DOI: 10.3389/fphar.2022.1033017.

The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression.

Xia L, Chen J, Huang M, Mei J, Lin M Front Oncol. 2022; 12:963617.

PMID: 35928868 PMC: 9343830. DOI: 10.3389/fonc.2022.963617.

Functional interplay between long non-coding RNAs and Breast CSCs.

Hussen B, Kheder R, Abdullah S, Hidayat H, Rahman H, Salihi A Cancer Cell Int. 2022; 22(1):233.

PMID: 35864503 PMC: 9306174. DOI: 10.1186/s12935-022-02653-4.

References

Mei P, Bai J, Liu H, Li C, Wu Y, Yu Z . RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol. 2011; 137(12):1823-30. DOI: 10.1007/s00432-011-1063-4. View

Lu X, Yu J, Ying L, Han J, Wang S, Yu Q . Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer. 2012; 118(22):5507-17. DOI: 10.1002/cncr.27604. View

Panda S, Setia M, Kaur N, Shepal V, Arora V, Singh D . Noncoding RNA Ginir functions as an oncogene by associating with centrosomal proteins. PLoS Biol. 2018; 16(10):e2004204. PMC: 6193740. DOI: 10.1371/journal.pbio.2004204. View

Zhang X, He H, Zhang X, Guo W, Wang Y . RUNX3 Promoter Methylation Is Associated with Hepatocellular Carcinoma Risk: A Meta-Analysis. Cancer Invest. 2015; 33(4):121-5. DOI: 10.3109/07357907.2014.1003934. View

Yang R, Xing L, Wang M, Chi H, Zhang L, Chen J . Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer. Cell Physiol Biochem. 2018; 50(2):473-488. DOI: 10.1159/000494162. View

Wang G, Chen X, Liang Y, Wang W, Fang Y, Shen K . Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. J Breast Cancer. 2018; 21(3):277-287. PMC: 6158153. DOI: 10.4048/jbc.2018.21.e39. View

Yu H, Wang S, Zhu H, Rao D . Retracted: LncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer. J Cell Physiol. 2019; 234(9):16160-16167. DOI: 10.1002/jcp.28274. View

Caballero D, Kaushik S, Correlo V, Oliveira J, Reis R, Kundu S . Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient. Biomaterials. 2017; 149:98-115. DOI: 10.1016/j.biomaterials.2017.10.005. View

Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N . The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 2014; 120(15):2299-307. DOI: 10.1002/cncr.28725. View

10.

Spizzo R, Almeida M, Colombatti A, Calin G . Long non-coding RNAs and cancer: a new frontier of translational research?. Oncogene. 2012; 31(43):4577-87. PMC: 3433647. DOI: 10.1038/onc.2011.621. View

11.

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

12.

Kim H, Park J, Lee S, Kim K, Park K, Chung W . Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer. J Pathol. 2015; 237(4):520-31. PMC: 4832375. DOI: 10.1002/path.4597. View

13.

Chen F, Wang M, Bai J, Liu Q, Xi Y, Li W . Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer. PLoS One. 2014; 9(1):e86917. PMC: 3901713. DOI: 10.1371/journal.pone.0086917. View

14.

Gupta S, Silveira D, Mombach J . ATM/miR-34a-5p axis regulates a p21-dependent senescence-apoptosis switch in non-small cell lung cancer: a Boolean model of G1/S checkpoint regulation. FEBS Lett. 2019; 594(2):227-239. DOI: 10.1002/1873-3468.13615. View

15.

Farghadani R, Seifaddinipour M, Rajarajeswaran J, Abdulla M, Mohd Hashim N, Khaing S . acute toxicity evaluation and molecular mechanism study of antiproliferative activity of a novel indole Schiff base -diiminato manganese complex in hormone-dependent and triple negative breast cancer cells. PeerJ. 2019; 7:e7686. PMC: 6786247. DOI: 10.7717/peerj.7686. View

16.

Xu Y, Zhang G, Zou C, Zhang H, Gong Z, Wang W . LncRNA MT1JP Suppresses Gastric Cancer Cell Proliferation and Migration Through MT1JP/MiR-214-3p/RUNX3 Axis. Cell Physiol Biochem. 2018; 46(6):2445-2459. DOI: 10.1159/000489651. View

17.

Zhang G, Li S, Lu J, Ge Y, Wang Q, Ma G . LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer. 2018; 17(1):87. PMC: 5930724. DOI: 10.1186/s12943-018-0829-6. View

18.

Maimaiti Y, Dong L, Aili A, Maimaitiaili M, Huang T, Abudureyimu K . Bim may be a poor prognostic biomarker in breast cancer patients especially in those with luminal A tumors. Cancer Biomark. 2017; 19(4):411-418. DOI: 10.3233/CBM-160377. View

19.

DeSantis C, Ma J, Sauer A, Newman L, Jemal A . Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017; 67(6):439-448. DOI: 10.3322/caac.21412. View

20.

Zhou C, Wang X, Yang N, Xue S, Li W, Xie P . LncRNA LET function as a tumor suppressor in breast cancer development. Eur Rev Med Pharmacol Sci. 2018; 22(18):6002-6007. DOI: 10.26355/eurrev_201809_15935. View